A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database Cohort

作者：Mean, C. V.; Saphonn, V.; Khol, V.; Zhang, F. J.; Zhao, H. X.; Han, N.; Lee, M. P.; Li, P. C. K.; Lam, W.; Chan, Y. T.; Kumarasamy, N.; Saghayam, S.; Ezhilarasi, C.; Pujari, S.; Joshi, K.; Gaikwad, S.; Chitalikar, A.; Merati, T. P.; Wirawan, D. N.; Yuliana, F.; Yunihastuti, E.; Imran, D.; Widhani, A.; Oka, S.; Tanuma, J.; Nishijima, T.; Choi, J. Y.; Na, S.; Kim, J. M.; Sim, B. L. H.; Gani, Y. M.; David, R.; Kamarulzaman, A.; Omar, S. F. Syed; Ponnampalavanar, S.; Azwa, I.; Mustafa, M.

来源：AIDS Research and Human Retroviruses, 2016, 32(8): 772-781.

DOI：10.1089/aid.2015.0294

• FOLLOW-UP
• IMMUNOLOGICAL RESPONSE
• PACIFIC REGION
• THERAPY
• OUTCOMES
• CARE
• INITIATION
• MORTALITY
• ADHERENCE
• DISEASE

Asian countries have seen the expansion of combination antiretroviral therapy (cART) over the past decade. The TREAT Asia HIV Observational Database (TAHOD) was established in 2003 comprising 23 urban referral sites in 13 countries across the region. We examined trends in treatment outcomes in patients who initiated cART between 2003 and 2013. Time of cART initiation was grouped into three periods: 2003-2005, 20062009, and 2010-2013. We analyzed trends in undetectable viral load (VL; defined as VL <400 copies/ml), CD4 changes from pre-cART levels, and overall survival. Of 6,521 patients included, the overall median CD4 count at cART initiation was 120 cells/mu l (interquartile range: 38-218). Despite an increase over time, pre-cART CD4 counts remained < 200 cells/mu l. Adjusted analyses showed undetectable VL was more likely when starting cART in later years [2006-2009: odds ratio (OR) = 1.76, 95% confidence interval (CI) (1.45, 2.15); and 2010-2013: OR=3.04, 95% CI (2.33, 3.97), all p < .001, compared to 2003-2005], and survival was improved [2006-2009: subdistribution hazard ratio (SHR) = 0.41, 95% CI (0.27, 0.61), 2010-2013: SHR = 0.29, 95% CI (0.17, 0.49), all p < .001, compared to 2003-2005]. No differences in CD4 response was observed over time. Age and CD4 levels prior to cART initiation were associated with all three treatment outcomes, with older age and higher CD4 counts being associated with undetectable VL. Survival and VL response on cART have improved over the past decade in TAHOD, although CD4 count at cART initiation remained low. Greater effort should be made to facilitate earlier HIV diagnosis and linkage to care and treatment, to achieve greater improvements in treatment outcomes.

• 出版日期2016-8
• 单位首都医科大学; 北京地坛医院